<p>, /PRNewswire/ -- Kessler Topaz Meltzer &amp; Check, LLP（www.ktmc.com）目前正在调查 uniQure N.V.（NASDAQ: QURE）（&#34;uniQure&#34;）投资者可能违反联邦证券法的情况。</p>
<p>2025 年 11 月 3 日，uniQure 发布了一份新闻稿，透露 FDA 通知公司，其针对亨廷顿舞蹈症的研究性基因疗法 AMT-130 的数据未能提供足够的证据来支持 uniQure 的生物制品许可申请（&#34;BLA&#34;）提交。具体而言，uniQure 披露公司认为 FDA 目前不再同意 AMT-130 的 I/II 期研究数据可能足以作为 BLA 提交的主要证据，并且由于这一原因，AMT-130 的 BLA 提交时间现在变得不明确。</p>
<p>在这一消息发布后，uniQure 的股价下跌超过 50%，从 2025 年 10 月 31 日的收盘价 67.69 美元跌至 2025 年 11 月 3 日的收盘价 34.29 美元。</p>
<p><strong><em>如果您是 uniQure 的投资者并希望了解更多关于我们调查的信息，请点击此处填写我们的在线表格或联系 Kessler Topaz Meltzer &amp; Check, LLP：Jonathan Naji, Esq. (484) 270-1453 或发送电子邮件至 [email protected].</em></strong> <strong><em>您也可以点击以下链接或将其粘贴到您的浏览器中：</em></strong> https://www.ktmc.com/uniqure-nv-investigation?utm_source=PR_Newswire&amp;mktm=PR</p>
<p>Kessler Topaz Meltzer &amp; Check, LLP 在全国各州和联邦法院起诉涉及证券欺诈、违反信托责任和其他州及联邦法律的集体诉讼。Kessler Topaz Meltzer &amp; Check, LLP 是公司治理改革的推动力量，已为来自美国及全球的机构和个人投资者追回数十亿美元。该事务所代表投资者、消费者和举报人（向政府报告欺诈行为的私人公民，并分享政府资金的追回）。有关 Kessler Topaz Meltzer &amp; Check, LLP 的更多信息，请访问 www.ktmc.com。</p>
<p>联系方式：</p>
<p>Kessler Topaz Meltzer &amp; Check, LLP</p>
<p>Jonathan Naji, Esq.</p>
<p>280 King of Prussia Road</p>
<p>Radnor, PA 19087</p>
<p>(484) 270-1453</p>
<p>[email protected]</p>
<p>在某些司法管辖区可能被视为律师广告。过去的结果并不保证未来的结果。</p>
<p>来源 Kessler Topaz Meltzer &amp; Check, LLP</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTIyJk5ld3NJdGVtSWQ9REMzMTE2NCZUcmFuc21pc3Npb25fSWQ9MjAyNTExMjIxMTQwUFJfTkVXU19VU1BSX19fX19EQzMxMTY0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTIyJk5ld3NJdGVtSWQ9REMzMTE2NCZUcmFuc21pc3Npb25fSWQ9MjAyNTExMjIxMTQwUFJfTkVXU19VU1BSX19fX19EQzMxMTY0"/></p>

QURE

<p>Kessler Topaz Meltzer & Check, LLP 正在调查 uniQure N.V.（NASDAQ: QURE）可能违反联邦证券法的情况，此前 FDA 表示其 AMT-130 基因疗法的数据不足以支持生物制品许可申请。这导致 uniQure 的股价下跌了 50%。遭受重大损失的投资者被鼓励与该公司联系以获取更多信息</p>

<p>, /PRNewswire/ -- The law firm of Kessler Topaz Meltzer &amp; Check, LLP (www.ktmc.com) is currently investigating potential violations of the federal securities laws on behalf of investors of uniQure N.V. (NASDAQ: QURE) (&#34;uniQure&#34;).</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Kessler Topaz Meltzer &amp; Check, LLP（www.ktmc.com）目前正在调查 uniQure N.V.（NASDAQ: QURE）（&#34;uniQure&#34;）投资者可能违反联邦证券法的情况。</p>
</div><p>On November 3, 2025, uniQure issued a press release revealing that the FDA notified the company that data for its AMT-130, an investigational gene therapy for Huntington's disease, did not provide sufficient evidence to support uniQure's Biologics License Application (&#34;BLA&#34;) submission. Specifically, uniQure disclosed that the company believes the FDA currently no longer agrees that data from the Phase I/II studies of AMT-130 may be adequate to provide the primary evidence in support of a BLA submission, and that the timing of the BLA submission for AMT-130 is now unclear as a result.</p>
<div class="lb-trans"><p>2025 年 11 月 3 日，uniQure 发布了一份新闻稿，透露 FDA 通知公司，其针对亨廷顿舞蹈症的研究性基因疗法 AMT-130 的数据未能提供足够的证据来支持 uniQure 的生物制品许可申请（&#34;BLA&#34;）提交。具体而言，uniQure 披露公司认为 FDA 目前不再同意 AMT-130 的 I/II 期研究数据可能足以作为 BLA 提交的主要证据，并且由于这一原因，AMT-130 的 BLA 提交时间现在变得不明确。</p>
</div><p>On this news, the price of uniQure's stock fell over 50%, from a close of $67.69 on October 31, 2025, to close at $34.29 on November 3, 2025.</p>
<div class="lb-trans"><p>在这一消息发布后，uniQure 的股价下跌超过 50%，从 2025 年 10 月 31 日的收盘价 67.69 美元跌至 2025 年 11 月 3 日的收盘价 34.29 美元。</p>
</div><p><strong><em>If you are a uniQure investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer &amp; Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or E-mail at [email protected].</em></strong> <strong><em>You can also click on the following link or paste it in your browser:</em></strong> https://www.ktmc.com/uniqure-nv-investigation?utm_source=PR_Newswire&amp;mktm=PR</p>
<div class="lb-trans"><p><strong><em>如果您是 uniQure 的投资者并希望了解更多关于我们调查的信息，请点击此处填写我们的在线表格或联系 Kessler Topaz Meltzer &amp; Check, LLP：Jonathan Naji, Esq. (484) 270-1453 或发送电子邮件至 [email protected].</em></strong> <strong><em>您也可以点击以下链接或将其粘贴到您的浏览器中：</em></strong> https://www.ktmc.com/uniqure-nv-investigation?utm_source=PR_Newswire&amp;mktm=PR</p>
</div><p>Kessler Topaz Meltzer &amp; Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer &amp; Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer &amp; Check, LLP, please visit www.ktmc.com.</p>
<div class="lb-trans"><p>Kessler Topaz Meltzer &amp; Check, LLP 在全国各州和联邦法院起诉涉及证券欺诈、违反信托责任和其他州及联邦法律的集体诉讼。Kessler Topaz Meltzer &amp; Check, LLP 是公司治理改革的推动力量，已为来自美国及全球的机构和个人投资者追回数十亿美元。该事务所代表投资者、消费者和举报人（向政府报告欺诈行为的私人公民，并分享政府资金的追回）。有关 Kessler Topaz Meltzer &amp; Check, LLP 的更多信息，请访问 www.ktmc.com。</p>
</div><p>CONTACT:</p>
<div class="lb-trans"><p>联系方式：</p>
</div><p>Kessler Topaz Meltzer &amp; Check, LLP</p>
<div class="lb-trans"><p>Kessler Topaz Meltzer &amp; Check, LLP</p>
</div><p>Jonathan Naji, Esq.</p>
<div class="lb-trans"><p>Jonathan Naji, Esq.</p>
</div><p>280 King of Prussia Road</p>
<div class="lb-trans"><p>280 King of Prussia Road</p>
</div><p>Radnor, PA 19087</p>
<div class="lb-trans"><p>Radnor, PA 19087</p>
</div><p>(484) 270-1453</p>
<div class="lb-trans"><p>(484) 270-1453</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.</p>
<div class="lb-trans"><p>在某些司法管辖区可能被视为律师广告。过去的结果并不保证未来的结果。</p>
</div><p>SOURCE Kessler Topaz Meltzer &amp; Check, LLP</p>
<div class="lb-trans"><p>来源 Kessler Topaz Meltzer &amp; Check, LLP</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUxMTIyJk5ld3NJdGVtSWQ9REMzMTE2NCZUcmFuc21pc3Npb25fSWQ9MjAyNTExMjIxMTQwUFJfTkVXU19VU1BSX19fX19EQzMxMTY0" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC31164&amp;Transmission_Id=202511221140PR_NEWS_USPR_____DC31164&amp;DateId=20251122"/></p>

11:40 ET
			
			
				QURE Investigation Notification: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

QURE 调查通知：Kessler Topaz Meltzer & Check, LLP 鼓励在 Uniqure N.V. (NASDAQ: QURE) 上遭受重大损失的投资者与该公司联系